CR20140413A - Inhibidores de serina/treonina cinasa - Google Patents

Inhibidores de serina/treonina cinasa

Info

Publication number
CR20140413A
CR20140413A CR20140413A CR20140413A CR20140413A CR 20140413 A CR20140413 A CR 20140413A CR 20140413 A CR20140413 A CR 20140413A CR 20140413 A CR20140413 A CR 20140413A CR 20140413 A CR20140413 A CR 20140413A
Authority
CR
Costa Rica
Prior art keywords
treonina
serina
cinasa
inhibitors
cinasa inhibitors
Prior art date
Application number
CR20140413A
Other languages
English (en)
Spanish (es)
Inventor
James F Blake
Mark Joseph Chicarelli
Rustam Ferdinand Garrey
John Gaudino
Jonas Grina
David A Moreno
Peter J Mohr
Li Ren
Jacob Schwarz
Huifen Chen
Kirk Robarge
Aihe Zhou
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR20140413A publication Critical patent/CR20140413A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20140413A 2012-03-01 2014-09-08 Inhibidores de serina/treonina cinasa CR20140413A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605523P 2012-03-01 2012-03-01
PCT/US2013/028622 WO2013130976A1 (en) 2012-03-01 2013-03-01 Serine/threonine kinase inhibitors

Publications (1)

Publication Number Publication Date
CR20140413A true CR20140413A (es) 2014-11-05

Family

ID=47892024

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140413A CR20140413A (es) 2012-03-01 2014-09-08 Inhibidores de serina/treonina cinasa

Country Status (36)

Country Link
US (4) US8697715B2 (enExample)
EP (2) EP3321262B1 (enExample)
JP (2) JP6068515B2 (enExample)
KR (1) KR102093526B1 (enExample)
CN (2) CN104507926B (enExample)
AR (2) AR090220A1 (enExample)
AU (1) AU2013225737B2 (enExample)
BR (1) BR112014021634B1 (enExample)
CA (1) CA2866086C (enExample)
CL (1) CL2014002301A1 (enExample)
CO (1) CO7081155A2 (enExample)
CR (1) CR20140413A (enExample)
CY (1) CY1120172T1 (enExample)
DK (2) DK2820009T3 (enExample)
ES (2) ES2665073T3 (enExample)
HR (2) HRP20180591T1 (enExample)
HU (2) HUE037423T2 (enExample)
IL (2) IL234376A (enExample)
LT (2) LT3321262T (enExample)
MX (1) MX354675B (enExample)
MY (1) MY191936A (enExample)
NO (1) NO2945854T3 (enExample)
NZ (1) NZ700314A (enExample)
PE (1) PE20150666A1 (enExample)
PH (3) PH12015501654A1 (enExample)
PL (2) PL2820009T3 (enExample)
PT (2) PT2820009T (enExample)
RS (2) RS61500B1 (enExample)
RU (1) RU2650501C2 (enExample)
SG (1) SG11201405356QA (enExample)
SI (2) SI2820009T1 (enExample)
SM (1) SMT201800282T1 (enExample)
TW (1) TWI589569B (enExample)
UA (1) UA116774C2 (enExample)
WO (1) WO2013130976A1 (enExample)
ZA (2) ZA201406688B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6085866B2 (ja) 2011-02-28 2017-03-01 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼインヒビター
BR112014002675A2 (pt) 2011-08-04 2017-02-21 Array Biopharma Inc "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
PL2820009T3 (pl) * 2012-03-01 2018-09-28 Array Biopharma, Inc. Inhibitory kinaz serynowo/treoninowych
MX363118B (es) * 2012-05-03 2019-03-11 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
CA2882750A1 (en) 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN104755478B (zh) 2012-10-16 2017-10-10 霍夫曼-拉罗奇有限公司 丝氨酸/苏氨酸激酶抑制剂
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
KR101910720B1 (ko) 2013-11-01 2018-10-22 노파르티스 아게 키나제 억제제로서의 아미노헤테로아릴 벤즈아미드
CR20160309A (es) 2013-12-06 2016-08-25 Genentech Inc Inhibidores de serina/treonina cinasa
WO2015103137A1 (en) 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
JP6487925B2 (ja) * 2013-12-30 2019-03-20 ジェネンテック， インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
HRP20191306T1 (hr) * 2014-04-09 2019-10-18 Genentech, Inc. Postupak proizvodnje lijekova
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
WO2016106009A1 (en) 2014-12-22 2016-06-30 Eli Lilly And Company Erk inhibitors
EP3303335B1 (en) * 2015-06-03 2021-07-28 JS Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
CN107849046B (zh) * 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
AU2016341445B2 (en) * 2015-10-23 2020-08-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
TWI730012B (zh) 2015-11-09 2021-06-11 瑞典商阿斯特捷利康公司 化學化合物
WO2017087905A1 (en) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
MX2018012471A (es) 2016-04-15 2019-02-21 Genentech Inc Metodos de diagnostico y terapeuticos para el cancer.
PE20190395A1 (es) 2016-06-16 2019-03-13 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
WO2019037640A1 (en) * 2017-08-22 2019-02-28 Js Innopharm (Shanghai) Ltd HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USING THE SAME
KR102730718B1 (ko) * 2017-08-23 2024-11-14 스프린트 바이오사이언스 아베 피리딜피리돈 화합물
TW202428305A (zh) 2017-09-08 2024-07-16 美商建南德克公司 癌症之診斷及治療方法
SG11202003920QA (en) 2017-11-24 2020-06-29 Novartis Ag Pyridinone derivatives and their use as selective alk-2 inhibitors
WO2019154364A1 (zh) * 2018-02-08 2019-08-15 南京明德新药研发有限公司 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
CN112638917B (zh) * 2018-05-22 2023-09-08 捷思英达控股有限公司 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
WO2020192750A1 (zh) * 2019-03-28 2020-10-01 江苏恒瑞医药股份有限公司 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
CN113784970B (zh) * 2019-05-15 2022-11-29 南京明德新药研发有限公司 Erk抑制剂及其应用
WO2021025407A1 (ko) 2019-08-02 2021-02-11 웰마커바이오 주식회사 옥소-피리딘 융합고리 유도체 및 이를 포함하는 약학적 조성물
WO2022100586A1 (zh) * 2020-11-11 2022-05-19 南京明德新药研发有限公司 一种含氧杂环丁烷的螺环类化合物的晶型、制备方法及其应用
CN115413669B (zh) * 2022-06-14 2024-03-15 湖南大学 激酶抑制剂及其组合剂在提高植物青枯病抗性中的应用
WO2025067459A2 (en) 2023-09-29 2025-04-03 D3 Bio (Wuxi) Co., Ltd. Therapies for the treatment of cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325113T1 (de) 1993-10-01 2006-06-15 Novartis Pharma Gmbh Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CN1328277C (zh) 1996-12-05 2007-07-25 安姆根有限公司 取代的嘧啶酮和吡啶酮化合物和它们的应用
US6602872B1 (en) * 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
CN1438890A (zh) 2000-02-25 2003-08-27 弗·哈夫曼-拉罗切有限公司 腺苷受体调制剂
IL152023A0 (en) 2000-04-26 2003-04-10 Eisai Co Ltd Compounds having adenosine a2 receptor antagonism and pharmaceutical compositions containing the same
US7214685B2 (en) 2000-05-02 2007-05-08 Lutz F. Tietze Prodrugs for a selective cancer therapy
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI330183B (enExample) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US20050043315A1 (en) * 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
PL218749B1 (pl) * 2002-02-14 2015-01-30 Pharmacia Corp Pochodna pirydynonu oraz jej zastosowanie do wytwarzania leku
JP4606161B2 (ja) * 2002-05-21 2011-01-05 アムジエン・インコーポレーテツド 置換複素環式化合物および使用方法
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2004007468A1 (en) 2002-07-15 2004-01-22 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
CL2004002050A1 (es) * 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
AU2005232745A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyrimidines as potassium ion channel modulators
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2578122A1 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
JP2008536950A (ja) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
ES2353437T3 (es) 2006-02-16 2011-03-02 Schering Corporation Derivados de pirrolidina como inhibidores de erk.
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
KR20090052884A (ko) 2006-08-23 2009-05-26 화이자 프로덕츠 인크. Ｇｓｋ-3 억제제로서의 피리미돈 화합물
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2008079933A2 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
HRP20100429T1 (hr) 2007-02-01 2010-09-30 Tibotec Pharmaceuticals Postupci i intermedijeri za pripravu makrocikličkog inhibitora proteaze za hcv
CA2685588A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Sa Fungicide heterocyclyl-pyrimidinyl-amino derivatives
ES2535166T3 (es) 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
CN101902912A (zh) 2007-11-06 2010-12-01 纳幕尔杜邦公司 杀真菌杂环胺
SG188179A1 (en) 2008-02-21 2013-03-28 Merck Sharp & Dohme Compounds that are erk inhibitors
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
EP2361248B1 (en) 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
SG192439A1 (en) 2008-06-27 2013-08-30 Novartis Ag Organic compounds
US8940891B2 (en) 2008-12-08 2015-01-27 Arena Pharmaceuticals, Inc. Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
DE102009051799B4 (de) 2009-11-03 2021-07-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bifunktionale Prodrugs und Drugs
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
WO2012020786A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
JP6085866B2 (ja) 2011-02-28 2017-03-01 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼインヒビター
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
BR112014002675A2 (pt) 2011-08-04 2017-02-21 Array Biopharma Inc "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
PL2820009T3 (pl) * 2012-03-01 2018-09-28 Array Biopharma, Inc. Inhibitory kinaz serynowo/treoninowych
CA2882750A1 (en) 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
KR102244553B1 (ko) 2013-08-23 2021-04-23 가부시키가이샤 한도오따이 에네루기 켄큐쇼 용량 소자 및 반도체 장치
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015103137A1 (en) * 2013-12-30 2015-07-09 Array Biopharma Inc. Serine/threonine kinase inhibitors
JP6487925B2 (ja) * 2013-12-30 2019-03-20 ジェネンテック， インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
HRP20191306T1 (hr) * 2014-04-09 2019-10-18 Genentech, Inc. Postupak proizvodnje lijekova

Also Published As

Publication number Publication date
KR20140138820A (ko) 2014-12-04
HK1204323A1 (zh) 2015-11-13
AU2013225737B2 (en) 2018-03-01
CN104507926A (zh) 2015-04-08
LT3321262T (lt) 2021-06-10
BR112014021634B1 (pt) 2022-09-27
EP3321262A1 (en) 2018-05-16
DK2820009T3 (en) 2018-04-16
KR102093526B1 (ko) 2020-03-25
BR112014021634A8 (pt) 2018-01-30
CN104507926B (zh) 2016-08-31
HK1254429A1 (en) 2019-07-19
LT2820009T (lt) 2018-05-10
EP3321262B1 (en) 2021-01-13
SG11201405356QA (en) 2014-11-27
PH12015501653B1 (en) 2018-01-17
CN106349217B (zh) 2020-08-28
CO7081155A2 (es) 2014-10-10
HUE037423T2 (hu) 2018-08-28
EP2820009B1 (en) 2018-01-31
NO2945854T3 (enExample) 2018-07-21
MX2014010432A (es) 2015-02-04
SMT201800282T1 (it) 2018-07-17
PL3321262T3 (pl) 2021-06-28
MY191936A (en) 2022-07-19
PH12014501947A1 (en) 2014-11-24
RS57097B1 (sr) 2018-06-29
PH12014501947B1 (en) 2014-11-24
AR121879A2 (es) 2022-07-20
IL234376A (en) 2016-10-31
IL244276B (en) 2020-01-30
CL2014002301A1 (es) 2015-05-08
UA116774C2 (uk) 2018-05-10
AR090220A1 (es) 2014-10-29
DK3321262T3 (da) 2021-01-25
PL2820009T3 (pl) 2018-09-28
EP2820009A1 (en) 2015-01-07
US9708290B2 (en) 2017-07-18
US9259470B2 (en) 2016-02-16
PT2820009T (pt) 2018-04-12
HRP20210482T1 (hr) 2021-05-14
IL244276A0 (en) 2016-04-21
HRP20180591T1 (hr) 2018-05-18
US20160122316A1 (en) 2016-05-05
ES2665073T3 (es) 2018-04-24
CY1120172T1 (el) 2018-12-12
NZ700314A (en) 2016-08-26
PH12015501653A1 (en) 2017-04-10
US8697715B2 (en) 2014-04-15
HK1206011A1 (en) 2015-12-31
CA2866086C (en) 2020-06-09
CA2866086A1 (en) 2013-09-06
RU2650501C2 (ru) 2018-04-16
SI3321262T1 (sl) 2021-04-30
PT3321262T (pt) 2021-03-04
PH12015501654B1 (en) 2017-04-10
JP2015508828A (ja) 2015-03-23
US10519126B2 (en) 2019-12-31
JP2016027053A (ja) 2016-02-18
SI2820009T1 (en) 2018-05-31
CN106349217A (zh) 2017-01-25
PH12015501654A1 (en) 2017-04-10
ES2857649T3 (es) 2021-09-29
US20140249127A1 (en) 2014-09-04
US20180127393A1 (en) 2018-05-10
WO2013130976A1 (en) 2013-09-06
HUE053994T2 (hu) 2021-08-30
PE20150666A1 (es) 2015-05-06
TWI589569B (zh) 2017-07-01
ZA201508847B (en) 2023-01-25
MX354675B (es) 2018-03-15
TW201339146A (zh) 2013-10-01
US20130252934A1 (en) 2013-09-26
RU2014139601A (ru) 2016-04-20
JP6068515B2 (ja) 2017-01-25
ZA201406688B (en) 2017-08-30
RS61500B1 (sr) 2021-03-31

Similar Documents

Publication Publication Date Title
CR20140413A (es) Inhibidores de serina/treonina cinasa
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX2016008624A (es) Inhibidores de serina/treonina cinasa.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY32730A (es) Inhibidores de cyp17
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
MX2016010572A (es) Compuestos heterociclicos aromaticos como compuestos antiinflamatorios.
IN2014CN03803A (enExample)
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
CU20170007A7 (es) Compuestos de imidazopiridazina
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
EA201690214A1 (ru) Способ лечения гипертрофической кардиомиопатии
EA201791596A1 (ru) Пиразоловые соединения
AR111423A2 (es) Compuestos terapéuticos para el dolor y síntesis de estos
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam